Related Experiment Video
Updated: Jun 14, 2025
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
Overcoming Breast Cancer Drug Resistance: A Novel Approach Using siRNA-Mediated P-glycoprotein Downregulation to
Zahra Abbasfard1, Abbas Behzad-Behbahani2, Banafshe Rastegari2
1Department of Genetics, College of Science, Islamic Azad University, Kazerun Branch, Kazerun, Iran.
Purpose:
Cancer, the second leading cause of mortality worldwide, represents a global health challenge, primarily due to drug resistance. Vinorelbine is a chemotherapeutic agent that disrupts cancer cell growth by targeting microtubules and inducing apoptosis. However, drug resistance remains a formidable obstacle. This resistance is caused by various factors including genetic mutations, drug efflux mechanisms, and DNA repair systems. Resolution of this challenge requires an innovative approach. This study investigated the potential of small interfering RNA (siRNA) to target and downregulate a vinorelbine-resistant MCF-7/ADR breast cancer cell line.
Methods:
Cells were cultured in Dulbecco's modified Eagle's medium (DMEM) 10% fetal bovine serum/penicillin/streptomycin. An siRNA targeting ABCB1 was designed and synthesized, and the cells were transfected with siRNA at final concentrations of 10, 20, and 30 nM. The3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess cell viability. ABCB1 mRNA expression levels were determined by real-time polymerase chain reaction (PCR).
Results:
MCF-7 cells exhibited a higher sensitivity to vinorelbine than MCF-7/ADR cells. MCF-7/ADR cells exhibited resistance to vinorelbine at concentrations, 12.50 and 25.00 μM. Treatment with siRNA significantly reduced ABCB1 expression by 2.93-fold (P=0.0001). Similarly, co-treatment with siRNA and vinorelbine produced a substantial 2.89-fold decrease in ABCB1 gene expression in MCF-7 cells compared to that in MCF-7/ADR cells (P=0.0001).
Conclusion:
The results of the present study indicate that the concurrent use of siRNA and vinorelbine holds substantial promise as a therapeutic approach to overcome ABCB1-mediated multidrug resistance (MDR) in breast cancer. It is necessary to conduct comprehensive clinical trials to determine the true effectiveness of this combination therapy.
Insights
Small interfering RNA (siRNA) combined with vinorelbine shows promise in overcoming drug resistance in breast cancer. This approach targets ABCB1-mediated multidrug resistance, potentially improving chemotherapy effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer is a leading global cause of death, with drug resistance being a major challenge.
- Vinorelbine is a chemotherapy drug that targets microtubules but faces resistance issues.
- Multidrug resistance (MDR) in cancer is often mediated by efflux pumps like ABCB1.
Purpose of the Study:
- To investigate the potential of small interfering RNA (siRNA) to overcome vinorelbine resistance in breast cancer.
- To target and downregulate ABCB1 expression in a vinorelbine-resistant MCF-7/ADR cell line.
Main Methods:
- Cultured MCF-7/ADR breast cancer cells.
- Transfected cells with siRNA targeting ABCB1 at various concentrations.
- Assessed cell viability using MTT assay and measured ABCB1 mRNA expression via real-time PCR.
Main Results:
- MCF-7/ADR cells displayed significant resistance to vinorelbine.
- siRNA treatment significantly reduced ABCB1 gene expression by approximately 2.9-fold (P=0.0001).
- Combination therapy of siRNA and vinorelbine also substantially decreased ABCB1 expression.
Conclusions:
- Concurrent use of siRNA and vinorelbine is a promising strategy to overcome ABCB1-mediated MDR in breast cancer.
- Further clinical trials are necessary to validate the efficacy of this combination therapy.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
01:10Drugs that Destabilize Microtubules
01:06Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...